Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
In contrast to mothers with Attention Deficit/Hyperactivity Disorder (ADHD), the impact of
paternal ADHD in families and children with ADHD symptoms has not been studied, despite the
prevalence of ADHD in males. Thus, the investigators do not know the feasibility, impact on
treatment on the family and child, and effects of treating fathers relative to mothers with
ADHD. Paternal ADHD is associated with negative parenting and child conduct problems.
The investigators hypothesize that successfully treating parental ADHD in fathers will have a
beneficial effects on the family that will extend to the child. Specifically, the
investigators believe that stimulant medication ((Lisdexamfetamine (LDX) or a different ADHD
medication if poor response to LDX) with fathers will reduce father's ADHD symptoms and
improve parenting. Effects of stimulant treatment of fathers will be compared to Behavioral
Parent Training (BPT) on parenting, and paternal and child outcomes in fathers with ADHD who
have children between the ages of 3 -8.
As in the investigator's previous work, the investigators will bank paternal and child DNA
and RNA for later examination of pharmacogenetic and epigenetic effects (i.e. RNA) of
stimulant response.